Register Now for Our Webinar

ACD’s RNAscope Assay fully automated on the Leica Biosystems BOND RX, is becoming the method of choice for tissue-based gene expression analysis for target validation, target safety assessment and biomarker development. ACD has available off-the-shelf available greater than 10,000 targets and any new targets for any tissue and any species can be developed within 2 weeks. RNAscope technology surpassed its 500th reference publication recently with almost half of the references coming in the last 12 months. Continuing advances in RNAscope technology now enable a wide range of applications.

Join our expert speaker:
Chris Bunker, PHD, VP Business Development

When: November 9, 2016 12:00 PM  CST

What you will learn:

  • Detection of any mRNA in FFPE and frozen tissues
  • Isoform-specific exon-exon junction detection
  • Point mutations, SNP and tissue-based CRISPR edit validation
  • Single-copy viral RNA and DNA genome detection
  • AAV and Lentiviral vector, viral UTR and codon-optimized transcript detection
  • Cancer, Neuroscience, Infectious disease, Stem cell, inflammation applications

About the Expert:

Dr. Christopher Bunker: is the Vice President of Business Development at Advanced Cell Diagnostics (ACD) in Hayward, California. Dr. Bunker did his doctoral research in the laboratory of Dr. Robert E. Kingston at Harvard University, investigating the oncoprotein function in regulating gene expression and chromatin structure in cancer model systems. Dr. Bunker continued work in cancer biology with a Leukemia Society of America postdoctoral fellowship in the laboratory of Dr. Patrick O’Farrell at the University of California, San Francisco, where he investigated developmental cell cycle control mechanisms. Following his postdoctoral research, Dr. Bunker joined Genome Therapeutics Corporation (GTC) as a senior scientist in cancer functional genomics, where he established a gene expression profiling platform to cancer target discovery. Dr. Bunker also has an M.B.A from Boston University. Dr. Bunker has put his scientific knowledge to use in business development activities for ten years at Cell Signaling Technology (CST) and for the past six years at Advanced Cell Diagnostics.

 

Disclaimer: BOND RX is for research use only. Not for diagnostic procedures.

 

 

ABOUT US


Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow from biopsy to diagnosis. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence.

Register for the webinar

Our privacy promise:
your email will never be shared.